Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.
Source: NLP:nitrofurantoin monohydrate
Brand names: Nitrofurantoin Mono
Nitrofuran Antibacterial
Route: Oral
Contraindications
CONTRAINDICATIONS Anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug. Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age. Nitrofurantoin monohydrate/macrocrystals capsules are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. Nitrofurantoin monohydrate/macrocrystals capsules are also contraindicated in those patients with known hypersensitivity to nitrofurantoin.
Pregnancy & Breastfeeding
Pregnancy Teratogenic effects Pregnancy Category B. Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin. In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and a low incidence of minor and common malformations were observed. However, at 25 times the human dose, fetal malformations were not observed; the relevance of these findings to humans is uncertain. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Non-teratogenic effects Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary adenomas in the F1 generation mice at doses 19 times the human dose on a mg/kg basis. The relationship of this finding to potential human carcinogenesis is presently unknown. Because of the uncertainty regarding the human implications of these animal data, this drug should be used during pregnancy only if clearly needed.
3 interactions on record
Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.
Source: NLP:nitrofurantoin monohydrate
Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.
Source: NLP:nitrofurantoin monohydrate
Reduces both rate and extent of nitrofurantoin absorption through adsorption onto magnesium trisilicate surface.
Source: NLP:nitrofurantoin monohydrate